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XBP1 is part of the ER stress response, and when activated in cancer cells, it fosters tumor growth.
In this issue of Cell, Cubillos-Ruiz et al. demonstrate that XBP1 in tumor-infiltrating dendritic
cells blunts anti-tumor immunity. These findings further imply XBP1 as a relevant target for cancer
therapy.Unfolded protein accumulation in the
endoplasmic reticulum (ER) activates a
cellular stress response that is promoted
by the transcription factor XBP1 (Yoshida
et al., 2001). In cancer, XBP1 activation
within tumor cells directly promotes tumor
outgrowth andmetastasis (Romero-Ram-
irez et al., 2004; Chen et al., 2014). XBP1
also regulates immune cell functions,
including plasma cell differentiation
(Todd et al., 2008) andmacrophage proin-
flammatory cytokine production (Marti-
non et al., 2010); however, whether or
not XBP1 controls tumor-associated im-
mune responses remains unknown. New
research by Cubillos-Ruiz et al. in this
issue of Cell identifies XBP1 as a critical
driver of dendritic cell (DC) dysfunction
in the tumor microenvironment. DCs are
known to stimulate cytotoxic T cells and
can thus promote T cell-mediated tumor
rejection. This new study indicates that
tumor-associated DCs frequently activate
XBP1, which disrupts DC homeostasis
and prevents anti-tumor T cell immunity
(Cubillos-Ruiz et al., 2015).
To investigate ER stress responses
within DCs in vivo, Cubillos-Ruiz et al.
generated a mouse model that enables
selective deletion of XBP1 in DCs
(XBP1DC-KO) (Figure 1). By using this
model, they showed that XBP1 is not
necessary for DC survival. This finding
may be unexpected, considering that
the ER stress response is usually associ-
ated with increased cell survival, but it
suggests that ER stress induction in
DCs serves functions unrelated to cell
preservation.
The authors report several notable re-
sults from a series of experiments that
indicate that XBP1 expression in DCs ac-
celerates primary and metastatic ovarian1492 Cell 161, June 18, 2015 ª2015 Elseviercarcinoma. For example, they observe
that removing XBP1 from DCs at tumor
initiation is enough to reduce KrasG12D
p53–/– driven ovarian cancer growth.
Additionally, mice lacking XBP1 in DCs
survive longer when challenged with
orthotopic tumors than those with XBP1.
Finally, implanting tumor cells admixed
with XBP1-sufficient DCs accelerates
cancer progression, whereas XBP1-defi-
cient DCs delay this process.
Tumor (or tumor stroma)-derived fac-
tors likely trigger the ER stress response
in DCs because XBP1 activation is signif-
icantly higher in tumor-infiltrating DCs
than in splenic DCs. Nevertheless, these
factors’ identity requires more study.
Hypoxia activates XBP1 in cancer cells
but did not in DCs, at least in the experi-
mental models used, nor did immune-
suppressive cytokines like IL-10 and
TGF-b, thereby suggesting that different
mechanisms activate XBP1 in cancer
cells and DCs.
Interestingly, the authors found that
the ER stress response in DCs is associ-
ated with increased reactive oxygen
species (ROS) and lipid peroxidation
byproducts. One of these byproducts is
the reactive aldehyde 4-hydroxynonenal
(4-HNE), which forms stable adducts
with numerous proteins. DC treatment
with 4-HNE alone was sufficient to acti-
vate XBP1 and chaperone protein ex-
pression; thus, 4-HNE induces the ER
stress response in DCs. 4-HNE was not
detected in significant levels in tumor
ascites fluid, indicating that it is produced
within DCs.
Cubillos-Ruiz et al. also report that
tumor-infiltrating wild-type DCs accumu-
late intracellular lipids, whereas XBP1-
deficient DCs do not. XBP1 deficiencyInc.also reduces the expression of multiple
genes involved in lipid biosynthetic path-
ways. Accordingly, XBP1 likely promotes
lipid buildup in wild-type DCs (Figure 1).
Such lipid accumulation is known to
inhibit T cell priming functions (Herber
et al., 2010). Consequently, Cubillos-
Ruiz et al. report that XBP1 deletion en-
ables surface expression of MHC-I/
peptide complexes in DCs. XBP1 deletion
in DCs also increases anti-tumor CD4+
and CD8+ T cells but reduces T regulatory
cells in the tumor stroma, presumably due
to enhanced antigen presentation. T cells
are responsible for inhibiting tumor
growth in this experimental context
because adoptive T cell transfer from
tumor-bearing XBP1DC-KO mice (but not
from control animals) reduced tumor
burden in recipients challenged with
ovarian cancer cells.
The anti-tumor effects of XBP1-defi-
cient DCs indicate that targeting XBP1
may have therapeutic value. Cubillos-
Ruiz et al. used XBP1-targeting small
interfering RNA nanoparticles (referred
to as siXBP1) that preferentially deliver
their cargo in phagocytes, including DCs
and macrophages, in vivo. Administering
siXBP1 to ovarian cancer-bearing animals
enhanced anti-tumor T cell responses
and significantly prolonged mouse sur-
vival. siXBP1 treatment failed in T-cell-
deficient Rag2–/– mice, further indicating
that adaptive immune cells mediate the
therapeutic response.
In sum, this work has multiple levels of
significance. The researchers reveal a
previously unrecognized mechanism of
ER stress induction and lipid accumula-
tion in DCs. The process that they
describe inhibits anti-tumor T cell immu-
nity but can be targeted in therapy. In
Figure 1. Model of XBP1-Driven ER Stress in Dendritic Cells
(Left) XBP1WT DC. (Right) XBP1KO DC. Tumor-derived factors activate lipid peroxidation within DCs in a
ROS-dependent mechanism. Lipid peroxidation byproducts trigger ER stress responses that activate
XBP1. XBP1 activation is connected to lipid synthesis pathways that ultimately increase lipid load within
the DCs and inhibit DC-mediated T cell priming. Loss of XBP1 eliminates ER stress responses and lipid
synthesis/accumulation and enhances DC ability to prime anti-tumor T cell responses.fact, interventional therapy targeting
XBP1 could fight cancers in two ways:
by preventing cancer cell survival (when
the drugs reach tumor cells) and by
fostering protective immunity (when the
drugs reach DCs in the tumor microenvi-
ronment).
In considering how the authors’ results
may someday translate to new therapeu-
tic options, some key questions remain
unanswered. For example, the factors
instigating ROS production and lipid
accumulation within DCs require identifi-
cation. Candidates include TLR ligands
because they can activate XBP1 in mac-
rophages (Martinon et al., 2010). Also, itis unknown whether DCs’ lipid content
and ER stress profile increase as the dis-
ease progresses or vary among DC sub-
sets. Indeed, tumors contain distinct DC
populations that have different capacities
to stimulate T cell functions locally (Broz
et al., 2014), but whether these DC popu-
lations have different responses to ER
stressors requires study. Finally, it would
be helpful to define whether lipid-medi-
ated inhibition of DC functions always
depends on activating an ER stress
response. XBP1 regulates lipid meta-
bolism in the liver, and transcriptional sig-
natures indicate that lipid biosynthesis is
similarly affected by XBP1 in DCs (LeeCell 16et al., 2008). Yet the authors also
observed that DC treatment with oleate,
which may cause lipid accumulation
without activating ER stress (Karaskov
et al., 2006), also impairs T cell activation.
The answers to these questions are
important because they should clarify
how, and which, DCs are susceptible to
tumor co-option. A full understanding of
ER stress disruption of DC homeostasis
will enable additional avenues of thera-
peutic discovery.REFERENCES
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